Sinovac Biotech
Beijing · Founded 2001
About Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), and mumps, as well as animal rabies vaccine for canines. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for enterovirus 71 (against hand, foot, and mouth disease), of which the EV71 vaccine is currently in Phase III clinical trials, pneumococcal conjugate, pneumococcal polysaccharides, and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines.
Company Facts
- Founded: 2001
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $96.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2018)
- Ticker: nasdaq:SVA
- Website: sinovac.com
- Phone: +86 10 8289 0088
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/sinovac-biotech-93576 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.